Drugs / PBA-0111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06700070 | Mar → Dec 2025 overdue | head and neck squamous cell carcinoma, soft tissue sarcoma, triple-negative breast carcinoma | Pure Biologics S.A. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-07-17 | Pure Biologics S.A. | Regulatory PB003G project – the FDA approval to proceed with Phase 0 clinical trial multiqure.com ↗
Pure Biologics has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase 0 clinical trial in Project PB003G for the PBA-0111 molecule. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-07-17 | Pure Biologics S.A. | PB003G project – the FDA approval to proceed with Phase 0 clinical trial multiqure.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBA-0111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06700070 ↗ |